Immune restoration in human immunodeficiency virus and hepatitis C virus coinfected patients after highly active antiretroviral therapy

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 5, 2013, Pages 551-554

  Antonello, Vicente Sperb ^a,b,c   Appel da Silva, Marcelo Campos ^b   Kliemann, Dimas Alexandre ^b   Santos, Breno Riegel ^b   Tovo, Cristiane Valle ^b,c  

^a Hospital Femina   (Brazil)

^b HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

CD4; Coinfection; HAART; Hepatitis C; HIV; Immunological response

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PROSPECTIVE STUDY; VIROLOGICAL RESPONSE; VIROLOGY; VIRUS LOAD;

CD4; COINFECTION; HAART; HEPATITIS C; HIV; IMMUNOLOGICAL RESPONSE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 84884710678     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.01.015     Document Type: Article

References (19)

1. Staples C.T., Rimland D., Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999, 29:150-154.
2. Hernandez M.D., Sherman K.E. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011, 6:478-482.
3. Babik J.M., Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on Hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. J Virol 2003, 77:1940-1950.
4. Tovo C.V., Santos D.E., Mattos A.Z., Almeida P.R.L., Mattos A.A., Santos B.R. Prevalência Ambulatorial em um Hospital Geral de marcadores para Hepatites B e C em pacientes com infecção pelo vírus da imunodeficiência humana. Arq Gastroenterol 2006, 43:73-76.
5. Santin M., Mestre M., Shaw E., et al. Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease. Eur J Clin Microbiol Infect Dis 2008, 27:65-73.
6. Peters L., Mocroft A., Soriano V., et al. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1 - infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009, 50:457-463.
7. Fuping G., Wei L., Yang H., et al. Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: multicentric observation cohort. J Acquir Immune Defic Syndr 2010, 54:137-142.
8. Antonucci G., Girardi E., Cozzi-Lepri A., et al. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis 2005, 40:e101-e109.
9. Yacisin K., Maida I., Ríos M.J., Soriano V., Núñez M. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24:935-940.
10. Valle Tovo C., Alves de Mattos A., Ribeiro de Souza A., et al. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int 2007, 27:40-46.
11. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
12. Macias J., Pineda J.A., Lozano F., et al. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis 2003, 22:675-680.
13. Potter M., Odueyungbo A., Yang H., Saeed S., Klein M.B. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 2010, 24:1857-1865. Canadian Co-infection Cohort Study Investigators.
14. Law W.P., Duncombe C.J., Mahanontharit A., et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004, 18:1169-1177.
15. Sulkowski M.S., Moore R.D., Mehta S.H., Chaisson R.E., Thomas D.L. Hepatitis C and progression of HIV disease. JAMA 2002, 288:199-206.
16. Mariné-Barjoan E., Saint-Paul M.C., Pradier C., et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004, 18:2163-2170.
17. John M., Flexman J., French M.A. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease. AIDS 1998, 12:2289-2293.
18. Bonfanti P., Valsecchi L., Parazzini F., et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000, 23:236-245.
19. Cooper C.L., Parbhakar M.A., Angel J.B. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002, 34:1259-1263.